Peritoneal fibrosis is characterized by abnormal production of extracellular matrix proteins
leading to progressive thickening of the submesothelial compact zone of the peritoneal …

Peritoneal dialysis (PD) is a renal replacement therapy for patients with end-stage renal
disease that is equivalent to hemodialysis with respect to adequacy, mortality, and other …

Peritoneal dialysis (PD) is an efficient renal replacement therapy for patients with end-stage
renal disease. Even if it ensures an outcome equivalent to hemodialysis and a better quality …

Peritoneal dialysis (PD) is limited by glucose-mediated peritoneal membrane (PM) fibrosis,
angiogenesis, and ultrafiltration failure. Influencing PM integrity by pharmacologically …

As a convenient, effective and economical kidney replacement therapy for end‐stage renal
disease (ESRD), peritoneal dialysis is available in approximately 11% of ESRD patients …

Long-term peritoneal dialysis (PD) causes structural and functional alterations of the
peritoneal membrane. Peritoneal deterioration and fibrosis are multicellular and …

GPI-anchored uPAR is the receptor for the extracellular serine protease urokinase-type
plasminogen activator (uPA). Though uPAR role in inflammatory processes is documented …

Peritoneal dialysis is a widely used method for treating kidney failure. However, over time,
the peritoneal structure and function can deteriorate, leading to the failure of this therapy …

A peritoneal adhesion (PA) is a fibrotic tissue connecting the abdominal or visceral organs to
the peritoneum. The formation of PAs can induce a variety of clinical diseases. However …

Baicalein (5, 6, 7-trihydroxyflavone) is a traditional Chinese medicine with multiple
pharmacological and biological activities including anti-inflammatory and anti-fibrotic effects …